HK1138187A1 - Nerve regeneration agent - Google Patents

Nerve regeneration agent

Info

Publication number
HK1138187A1
HK1138187A1 HK10103433.7A HK10103433A HK1138187A1 HK 1138187 A1 HK1138187 A1 HK 1138187A1 HK 10103433 A HK10103433 A HK 10103433A HK 1138187 A1 HK1138187 A1 HK 1138187A1
Authority
HK
Hong Kong
Prior art keywords
nerve regeneration
regeneration agent
agent
nerve
regeneration
Prior art date
Application number
HK10103433.7A
Other languages
English (en)
Inventor
Masanori Kontani
Yoshiyuki Ishikura
Noriko Oosumi
Motoko Maekawa
Original Assignee
Suntory Holdings Ltd
Univ Tohoku
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Holdings Ltd, Univ Tohoku filed Critical Suntory Holdings Ltd
Publication of HK1138187A1 publication Critical patent/HK1138187A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
HK10103433.7A 2006-12-28 2010-04-07 Nerve regeneration agent HK1138187A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006355854 2006-12-28
PCT/JP2007/075403 WO2008081989A1 (ja) 2006-12-28 2007-12-27 神経再生剤

Publications (1)

Publication Number Publication Date
HK1138187A1 true HK1138187A1 (en) 2010-08-20

Family

ID=39588655

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10103433.7A HK1138187A1 (en) 2006-12-28 2010-04-07 Nerve regeneration agent

Country Status (7)

Country Link
US (1) US8383677B2 (ja)
EP (2) EP3593797A1 (ja)
JP (3) JPWO2008081989A1 (ja)
KR (3) KR101881982B1 (ja)
CN (1) CN101631542B (ja)
HK (1) HK1138187A1 (ja)
WO (1) WO2008081989A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011136948A (ja) * 2009-12-28 2011-07-14 Nisshin Oillio Group Ltd うつ病又はうつ状態の予防又は治療用油脂組成物
EP2931292B1 (en) * 2012-12-13 2018-06-13 Warsaw Orthopedic, Inc. Compositions and methods comprising polyethylene glycol and magnesium for treatment of neuronal injury
JP6207545B2 (ja) * 2015-04-30 2017-10-04 丸大食品株式会社 学習記憶能力増強剤
CN108495627A (zh) * 2016-03-30 2018-09-04 雀巢产品技术援助有限公司 包含脂肪酸的组合物及其用途
JP6842093B2 (ja) * 2019-08-20 2021-03-17 丸大食品株式会社 学習記憶能力増強剤

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1112820A (en) 1967-04-28 1968-05-08 Standard Telephones Cables Ltd Improvements in or relating to electrical storage systems
US4668704A (en) * 1982-08-09 1987-05-26 Regents Of The University Of California Method for protecting and healing gastro-duodenal mucosa and the liver of mammals
US4526902A (en) * 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
GB8601915D0 (en) 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
US5658767A (en) 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
GB9224809D0 (en) 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
AU683027B2 (en) 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
JP3467794B2 (ja) 1993-03-09 2003-11-17 日本油脂株式会社 学習能向上剤
AU7053494A (en) 1993-06-04 1995-01-03 Martek Biosciences Corporation Method of treating coronary vascular disease using docosahexaenoic acid
CA2164291C (en) 1993-06-09 2007-10-30 David John Kyle Methods and pharmaceutical compositions useful for treating neurological disorders
ES2118629T3 (es) 1994-10-05 1998-09-16 Milupa Gmbh & Co Kg Mezcla de grasas conteniendo fosfolipidos con acidos grasos lcp
JPH08143454A (ja) 1994-11-17 1996-06-04 Kanagawa Kagaku Kenkyusho:Kk 神経成長因子産生増強剤
GB9423625D0 (en) 1994-11-23 1995-01-11 Scotia Holdings Plc Fortified fruit juice
US5583019A (en) * 1995-01-24 1996-12-10 Omegatech Inc. Method for production of arachidonic acid
JPH08214891A (ja) 1995-02-17 1996-08-27 Osaka City 高度不飽和脂肪酸含有トリグリセリドを含む油脂の製造方法
JPH0923817A (ja) 1995-07-07 1997-01-28 Nisshin Oil Mills Ltd:The 油脂含有飲食物
JPH0930962A (ja) 1995-07-21 1997-02-04 Nisshin Oil Mills Ltd:The 医療用油脂含有組成物
JP2863827B2 (ja) * 1995-12-28 1999-03-03 工業技術院長 ガス漏洩検知システム
CN1058845C (zh) 1996-01-31 2000-11-29 高世虎 强化营养豆奶粉
JP4034370B2 (ja) 1996-09-27 2008-01-16 雪印乳業株式会社 脳機能改善剤及び栄養組成物
JP4633204B2 (ja) 1996-10-11 2011-02-16 サントリーホールディングス株式会社 アラキドン酸含有食用油脂およびそれを含有する食品
JPH10155459A (ja) 1996-11-27 1998-06-16 Suntory Ltd アスタキサンチン含有飲食物
US6080787A (en) * 1997-02-21 2000-06-27 Abbott Laboratories Methods for reducing the incidence of necrotizing enterocolitis
FR2762993B1 (fr) 1997-05-06 1999-08-13 Inst Rech Biolog Sa Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique
US5902807A (en) * 1997-05-12 1999-05-11 Antti Haapalinna Method for the treatment of mental illness in mammals and a composition therefor
ATE230935T1 (de) 1997-07-22 2003-02-15 Nestle Sa Lipidzusammensetzung für säuglingsnährpräparat und herstellungsverfahren
JP2970804B2 (ja) 1997-07-23 1999-11-02 株式会社フジクラ 難燃性シート
US6225444B1 (en) * 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
JP4175698B2 (ja) 1998-06-19 2008-11-05 サントリー株式会社 新規なトリグリセリド及びそれを含む組成物
JP2002527387A (ja) 1998-10-15 2002-08-27 デーエスエム・ナムローゼ・フェンノートシャップ Ｐｕｆａサプリメント
IT1304406B1 (it) * 1998-10-21 2001-03-19 Danital Italia S R L Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3.
GB9916536D0 (en) 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
JP2001031586A (ja) 1999-07-14 2001-02-06 Sunstar Inc 動脈硬化症及び動脈硬化症に起因する疾患の予防又は治療組成物
GB9923738D0 (en) 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
US7208180B2 (en) * 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
US20020019444A1 (en) 2000-05-08 2002-02-14 Edward Hogestatt Anandamide and structurally related lipids as vanilloid receptor modulators
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
US20020077355A1 (en) 2000-05-30 2002-06-20 Liao James K. Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions
EP1292288B1 (en) 2000-06-23 2004-09-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
AU2001292586A1 (en) 2000-09-07 2002-03-22 University Of Maryland Biotechnology Institute Use of arachidonic acid for enhanced culturing of fish larvae and broodstock
ATE430794T1 (de) 2001-03-09 2009-05-15 Nestle Sa Öl, das langkettige, mehrfach ungesättigte fettsäuren aus biomassen enthält, verfahren zur herstellung, lebensmittel, nahrungsmittelzusammensetzung, kosmetische oder pharmazeutische zusammensetzung, die dieses enthält
GB0111282D0 (en) 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
ATE419858T1 (de) 2001-06-18 2009-01-15 Neptune Technologies & Bioress Krillextrakte zur prävention und/oder behandlung von herz-kreislauf-erkrankungen
CN101037641B (zh) 2001-07-02 2011-07-27 三得利控股株式会社 含有含多不饱和脂肪酸的甘油三酯的油或脂肪的生产方法
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
EP1413315A4 (en) * 2001-08-03 2006-08-16 Takeda Pharmaceutical DRUGS WITH CONTINUOUS RELEASE
JP2003113120A (ja) 2001-08-03 2003-04-18 Takeda Chem Ind Ltd 徐放性医薬
AU2003229993B2 (en) 2002-05-03 2008-07-24 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
TWI343418B (en) 2002-09-13 2011-06-11 Suntory Holdings Ltd Process for production of transesterified oils/fats or triglycerides
GB0221480D0 (en) 2002-09-16 2002-10-23 Laxdale Ltd Treatment of anorexia nervosa (AN) and bulimia
PT1542670E (pt) 2002-09-24 2013-07-11 Suntory Holdings Ltd Composição com efeitos na prevenção do declínio, melhoramento ou aumento de respostas normais de aptidões cognitivas de uma pessoa saudável
CN101843610A (zh) 2003-03-27 2010-09-29 三得利控股株式会社 花生四烯酸在制备具有使超昼夜节律正常化作用的组合物中的用途
JPWO2004091663A1 (ja) 2003-04-18 2006-07-06 協和醗酵工業株式会社 神経再生薬
DE112004001520B4 (de) * 2003-08-18 2008-04-10 Btg International Ltd. Verwendung eines Lipidglyzerids festgelegter Struktur zur Herstellung eines Medikamentes zur Behandlung der multiplen Sklerose
IL158552A0 (en) 2003-10-22 2004-05-12 Enzymotec Ltd Lipids containing omega-3 fatty acids
JP4522075B2 (ja) 2003-10-29 2010-08-11 サントリーホールディングス株式会社 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
US20090215896A1 (en) 2004-01-19 2009-08-27 Martek Biosciences Corporation Reelin deficiency or dysfunction and methods related thereto
JP4868199B2 (ja) 2004-09-10 2012-02-01 学校法人鈴鹿医療科学大学 サルビアノール酸ｂを有効成分とする神経幹細胞増殖剤
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP2006083136A (ja) 2004-09-17 2006-03-30 Suntory Ltd ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5697293B2 (ja) 2005-06-30 2015-04-08 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物

Also Published As

Publication number Publication date
KR101578498B1 (ko) 2015-12-18
JP2016065097A (ja) 2016-04-28
CN101631542A (zh) 2010-01-20
EP3593797A1 (en) 2020-01-15
US20100016433A1 (en) 2010-01-21
US8383677B2 (en) 2013-02-26
EP2098229A4 (en) 2010-03-10
KR20140117705A (ko) 2014-10-07
EP2098229A1 (en) 2009-09-09
WO2008081989A1 (ja) 2008-07-10
JP6150735B2 (ja) 2017-06-21
JP2014058579A (ja) 2014-04-03
CN101631542B (zh) 2011-12-21
KR20090085146A (ko) 2009-08-06
JPWO2008081989A1 (ja) 2010-04-30
JP6104356B2 (ja) 2017-03-29
KR101881982B1 (ko) 2018-07-25
KR20120116463A (ko) 2012-10-22
KR101430214B1 (ko) 2014-08-18

Similar Documents

Publication Publication Date Title
PL2089139T3 (pl) Ulepszona regeneracja absorbentu
PL2089138T3 (pl) Polepszona regeneracja absorbentu
TWI351125B (en) Hydrogen-processing assemblies
EP1855710A4 (en) MUSCLE REGENERATION
EP2083777A4 (en) RETINAL REGENERATION
HK1132912A1 (en) Muscle regeneration promoter
GB0624874D0 (en) Treatment
EP1991253A4 (en) NERVE REGENERATION USING KERATIN BIO-MATERIALS
IL197714A0 (en) 2-pyridinecarboxamide derivative having gk-activating activity
GB0600692D0 (en) Well treatment
EP2083902A4 (en) FILTER ARRANGEMENTS
GB0605107D0 (en) Use
EP2062892A4 (en) AGENT ENHANCING HYPERTENSION
GB0524283D0 (en) Regeneration means
GB0613209D0 (en) Methods
HK1138187A1 (en) Nerve regeneration agent
EP2030629A4 (en) AGENT FOR IMPROVING LIPID METABOLISM
GB0600967D0 (en) Methods
GB0624105D0 (en) Use
GB0608941D0 (en) Methods
EP2060263A4 (en) AGENT FOR IMPROVING LIPID METABOLISM
GB0505853D0 (en) Regeneration unit
GB0604460D0 (en) Treatment
EP2057992A4 (en) MEANS FOR IMPROVING THE KIDNEY FUNCTION
IL198189A0 (en) Filter assemblies